Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
FIB-4 is a non-invasive fibrosis risk score widely used in chronic liver disease triage, including NAFLD and viral hepatitis pathways. It helps identify low-risk patients versus those needing elastography or specialist evaluation.
Formula: FIB-4 = (Age x AST) / (Platelets x sqrt(ALT)).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
FIB-4 requires four inputs available from a standard complete blood count and liver function panel: patient age (years), AST (U/L), ALT (U/L), and platelet count (×10⁹/L, also reported as k/µL). These are routinely available at any outpatient or inpatient encounter. No special imaging or invasive testing is needed for the initial FIB-4 calculation.
FIB-4 = (Age × AST) / (Platelet count × √ALT). The numerator multiplies age and AST; the denominator multiplies platelet count by the square root of ALT. For example, a 55-year-old with AST 55 U/L, ALT 48 U/L, and platelets 210 ×10⁹/L: FIB-4 = (55 × 55) / (210 × √48) = 3025 / (210 × 6.93) = 3025 / 1455 = 2.08. Most EHR systems and hepatology order sets now calculate FIB-4 automatically.
Three zones guide clinical action: FIB-4 <1.30 = low fibrosis risk (F0-F1 by METAVIR); reassure patient and reassess annually. FIB-4 1.30–2.67 = indeterminate zone — refer for vibration-controlled transient elastography (VCTE/FibroScan) or other validated second-line test (ELF score, liver biopsy in selected cases). FIB-4 >2.67 = high fibrosis risk (likely F3-F4/cirrhosis); refer promptly to hepatology for comprehensive evaluation, portal hypertension assessment, and HCC surveillance consideration. In patients >65 years, age-adjusted thresholds (lower cutoff ≥2.0) reduce false positives.
Primary care physicians and internists
The 2023 AASLD/AGA Clinical Care Pathway recommends FIB-4 as the first-line non-invasive test for fibrosis assessment in all patients with NAFLD/MASLD. Calculate at diagnosis and annually to monitor progression or response to lifestyle intervention.
Infectious disease physicians and hepatologists
FIB-4 is validated in HCV-infected patients (including HIV/HCV co-infection where it was originally developed) for pre-treatment fibrosis staging and monitoring. FIB-4 >3.25 in HCV identifies patients likely to have cirrhosis needing additional monitoring.
Hepatologists and gastroenterologists
Serial FIB-4 measurements in chronic HBV infection help track fibrosis progression during antiviral therapy. Rising FIB-4 over time despite viral suppression may signal inadequate fibrosis regression or concurrent NAFLD.
Endocrinologists and metabolic medicine physicians
In patients with type 2 diabetes, obesity, or metabolic syndrome, FIB-4 identifies those at advanced fibrosis risk who need hepatology referral vs those who can be safely monitored in primary care with dietary counseling.
Hepatologists
For patients with FIB-4 <1.30 (low risk) or FIB-4 >2.67 (high risk), the clinical decision is clear and biopsy can often be avoided. The indeterminate zone (1.30–2.67) is where FibroScan or second-line NITs inform the need for biopsy.
All clinicians managing chronic liver disease
FIB-4 should be recalculated annually in patients with known NAFLD/MASLD. A rising FIB-4 that crosses from low to indeterminate or indeterminate to high risk zones indicates accelerating fibrosis and should prompt immediate hepatology referral.
The 2023 AASLD/AGA Multi-Society Clinical Care Pathway (Rinella et al., Gastroenterology 2023) explicitly recommends FIB-4 as the primary non-invasive tool for fibrosis assessment in MASLD, ahead of APRI and NAFLD Fibrosis Score due to its superior accuracy and simplicity.
In large validation cohorts, FIB-4 <1.30 has a negative predictive value exceeding 90% for METAVIR F2-F4 fibrosis. This makes it highly useful for ruling out significant fibrosis and safely avoiding elastography in the majority of low-risk NAFLD patients in primary care.
While not as high as the NPV, FIB-4 >2.67 identifies patients very likely to have F3-F4 disease. These patients should be referred to hepatology for FibroScan confirmation, HCC surveillance enrollment (if cirrhotic), esophageal variceal screening, and consideration of liver-directed therapy.
Approximately 20–40% of NAFLD patients fall in the indeterminate FIB-4 zone. Per AASLD/AGA 2023, these patients should proceed to vibration-controlled transient elastography (FibroScan/VCTE), the ELF score, or enhanced liver fibrosis test. Do not simply repeat FIB-4 in 3 months — it is unlikely to reclassify the patient without significant clinical change.
Because age is in the FIB-4 numerator, elderly patients (>60–65 years) systematically have higher FIB-4 values. McPherson et al. (J Hepatol 2017) proposed using a lower cutoff of 2.0 (instead of 2.67) as the upper threshold for the indeterminate zone in patients >65 years, reducing false-positive advanced fibrosis classifications in the elderly.
Acute AST or ALT spikes from any cause (viral hepatitis flares, drug-induced liver injury, ischemic hepatitis) elevate FIB-4 substantially. Do not calculate FIB-4 during an acute hepatocellular injury episode. Wait until transaminases return to baseline (or chronic level) before using FIB-4 for fibrosis staging.
FIB-4 divides by platelet count — any cause of low platelets (immune thrombocytopenia, hypersplenism, drug-induced thrombocytopenia, bone marrow suppression) will mathematically inflate FIB-4 independent of liver fibrosis. Always review the etiology of a low platelet count before attributing elevated FIB-4 to liver disease.
Multiple meta-analyses comparing FIB-4 and APRI across NAFLD, HCV, and HBV cohorts show FIB-4 has higher AUROC for advanced fibrosis (approximately 0.85 vs 0.78 for APRI). AASLD/AGA 2023 recommends FIB-4 as the preferred initial test over APRI in MASLD management pathways.
In chronic liver disease, progressive thrombocytopenia from hypersplenism (portal hypertension-induced splenic sequestration) drives FIB-4 upward — both directly (lower denominator) and as a signal of evolving cirrhosis. A patient whose platelet count is falling over serial measurements even while transaminases are stable may be developing clinically significant portal hypertension.
Body weight loss of 7–10% (or more) improves steatosis and inflammation and can improve NIT scores including FIB-4 over 12–24 months. Serial annual FIB-4 measurement provides objective tracking of fibrosis trajectory in patients undergoing lifestyle intervention, GLP-1 agonist therapy, or bariatric surgery evaluation.
FIB-4 was developed by Sterling et al. (Hepatology 2006) in 847 HIV/HCV co-infected patients and subsequently validated in NAFLD by Shah et al. (Clin Gastroenterol Hepatol 2009). AUROC for advanced fibrosis (≥F3) is approximately 0.85 in NAFLD and 0.87 in HCV. The 2023 AASLD/AGA Multi-Society Clinical Practice Guideline on MASLD (Rinella et al., Gastroenterology 2023) recommends FIB-4 as the primary non-invasive test for fibrosis assessment. Age-adjusted thresholds for patients >65 years were proposed by McPherson et al. (J Hepatol 2017).
Lower FIB-4 values suggest lower probability of advanced fibrosis, while higher values indicate greater risk and need for further evaluation.
Use FIB-4 for non-invasive fibrosis risk stratification in chronic liver disease pathways and primary care-to-hepatology triage.
FIB-4 can be confounded by acute transaminase elevations, age effects, and non-hepatic platelet abnormalities. It should not replace definitive fibrosis assessment when clinically indicated.
For related assessments, see MELD Score, Child-Pugh Score and AST/ALT Ratio.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the MELD and MELD-Na scores to assess liver disease severity and transplant priority. Uses bilirubin, INR, creatinine, and sodium.
OpenClinicalCalculate the Child-Pugh score to classify the severity of chronic liver disease and estimate prognosis. Uses bilirubin, albumin, INR, ascites, and encephalopathy.
OpenGastroenterologyCalculate the AST/ALT ratio as an adjunct liver injury pattern marker in hepatology evaluation.
OpenGastroenterologyCalculate the Glasgow-Blatchford score to identify low-risk upper GI bleed patients. Score 0–1: safe for outpatient endoscopy without admission. Higher scores guide urgency and ICU level of care.
OpenComprehensive guide to liver disease including NAFLD/NASH, alcoholic liver disease, viral hepatitis, cirrhosis pathophysiology, portal hypertension complications (varices, ascites, HRS), Child-Pugh score, MELD score, FIB-4, APRI, and liver transplant criteria.
Read guideReferenceLearn what liver function tests measure, what the key markers mean, and how clinical scoring systems assess liver disease severity.
Read guide